by Chris Mondics, Staff Writer @cmondics
A Philadelphia jury found Friday that the antipsychotic drug Risperdal caused a Tennessee boy to grow breasts and imposed a $70 million verdict on its manufacturer, Janssen Pharmaceuticals.
Lawyers for the boy argued that scientists for the company were well aware of the risks and sought to downplay them. The company disputed that allegation during the Common Pleas Court trial and said that physicians were fully informed of potential side effects.
It was the fifth Risperdal lawsuit tried in Philadelphia, and by far the largest verdict so far. Earlier verdicts ranged from $500,000 to $2.2 million.
"The jury got angry at these people; they don't take responsibility," said Stephen Sheller, one of the boy's lawyers.
Janssen, a subsidiary of Johnson & Johnson, said in a statement that it would appeal, and disputed that the drug had caused the boy to develop breasts.
Continue reading.
Thank You Philly.com and Mr Mondics.
Lawyers for the boy argued that scientists for the company were well aware of the risks and sought to downplay them. The company disputed that allegation during the Common Pleas Court trial and said that physicians were fully informed of potential side effects.
It was the fifth Risperdal lawsuit tried in Philadelphia, and by far the largest verdict so far. Earlier verdicts ranged from $500,000 to $2.2 million.
"The jury got angry at these people; they don't take responsibility," said Stephen Sheller, one of the boy's lawyers.
Janssen, a subsidiary of Johnson & Johnson, said in a statement that it would appeal, and disputed that the drug had caused the boy to develop breasts.
Continue reading.
Thank You Philly.com and Mr Mondics.
No comments:
Post a Comment